Standardization of criteria in MacCAT-T and MacCAT-CR for monoclonal anti-beta-amyloid antibodies: A Delphi study.

Alzheimers Dement (Amst) · 2025 · PMC12066392 · PMID 40357142

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Delphi outputs In the first wave, there was already a clear trend among the experts, so that for lecanemab 5/9 in the subpart of features, 3/6 in the subpart of benefits, and 17/21 in the area of risks received less than 25.0 % agreement, and for donanemab 6/10, 2/5, and 13/16, respectively.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.